Information Provided By:
Fly News Breaks for March 3, 2016
EXAS
Mar 3, 2016 | 09:07 EDT
Baird believes Exact Sciences is still appealing despite its initial growth falling short of expectations. The firm sees the shares as appealing and rewarding for patient investors and they believe the company will recover from its launch missteps. Baird reiterated its Outperform rating and $12 price target on Exact Sciences shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS